Two structurally different T-type Ca 2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats.
Bancila
M
M
Service de Neurochirurgie, Département des Neurosciences Cliniques, Hôpitaux Universitaires de Genève et Université de Genève, 1211 Geneva, Switzerland.
Copin
J-C
JC
Daali
Y
Y
Schatlo
B
B
Gasche
Y
Y
Bijlenga
Philippe
P
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D056547:CA1 Region, Hippocampal / Q000187:drug effects* / Q000473:pathology; D002121:Calcium Channel Blockers / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D020747:Calcium Channels, T-Type / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D055724:Electrophysiological Phenomena / Q000187:drug effects / Q000502:physiology; D005947:Glucose / Q000172:deficiency; D057809:HEK293 Cells; D006801:Humans; D000860:Hypoxia; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019344:Lactic Acid / Q000097:blood; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D020748:Mibefradil / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D018696:Neuroprotective Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010868:Pimozide / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis; D046509:Tissue Culture Techniques; D014162:Transfection
C479952:CACNA1H protein, human; D002121:Calcium Channel Blockers; D020747:Calcium Channels, T-Type; D018696:Neuroprotective Agents; D010868:Pimozide; D020748:Mibefradil; D019344:Lactic Acid; D005947:Glucose